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Missense mutations in the lysosomal hydrolase b-
galactocerebrosidase (GALC) account for at least 40% of
known cases of Krabbe disease (KD). Most of these mis-
sense mutations are predicted to disrupt the fold of the
enzyme, preventing GALC in sufficient amounts from
reaching its site of action in the lysosome. The predomi-
nant central nervous system (CNS) pathology and the
absence of accumulated primary substrate within the
lysosome mean that strategies used to treat other lysoso-
mal storage disorders (LSDs) are insufficient in KD, high-
lighting the still unmet clinical requirement for successful
KD therapeutics. Pharmacological chaperone therapy
(PCT) is one strategy being explored to overcome defects
in GALC caused by missense mutations. In recent stud-
ies, several small-molecule inhibitors have been identified
as promising chaperone candidates for GALC. This
Review discusses new insights gained from these studies
and highlights the importance of characterizing both the
chaperone interaction and the underlying mutation to
define properly a responsive population and to improve
the translation of existing lead molecules into successful
KD therapeutics. We also highlight the importance of
using multiple complementary methods to monitor PCT
effectiveness. Finally, we explore the exciting potential of
using combination therapy to ameliorate disease through
the use of PCTwith existing therapies or with more gener-
alized therapeutics, such as proteasomal inhibition, that
have been shown to have synergistic effects in other
LSDs. This, alongside advances in CNS delivery of
recombinant enzyme and targeted rational drug design,
provides a promising outlook for the development of KD
therapeutics. VC 2016 The Authors. Journal of Neuroscience
Research Published by Wiley Periodicals, Inc.
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Krabbe disease (KD; also known as globoid cell leuko-
dystrophy) is an autosomal recessive sphingolipidosis with a
severe and progressive neurodegenerative disease course
caused by deficiencies in the lysosomal hydrolase b-
galactocerebrosidase (GALC). GALC is required for the
hydrolysis of galactosphingolipids, including the major
lipid component of myelin b-galactocerebroside (GalCer)
required for lipid turnover and maintenance of the myelin
sheath that surrounds and protects neurons. Although KD
is classified as a lysosomal storage disorder (LSD), unlike
other LSDs, there is little to no storage of primary sub-
strate (Eto and Suzuki, 1970). Instead, GALC deficiency
results in the progressive accumulation of the cytotoxic
galactosphingolipid substrate psychosine (also known as
galactosylphingosine; Svennerholm et al., 1980; Igisu and
Suzuki, 1984). UDP-galactose:ceramide galatosyltransfer-
ase 8 catalyzes the synthesis of both GalCer and
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psychosine through the galactosylation of ceramide and
sphingosine, respectively (Suzuki, 2003). Under normal
physiological conditions, psychosine levels in the brain
are virtually undetected. However, in KD, GALC is
unable to break down the cytotoxic psychosine, and its
accumulation is widely accepted to be responsible for the
cell death associated with the rapid and widespread demy-
elination throughout both the CNS and the peripheral
nervous system observed in KD (Suzuki, 1998; Won
et al., 2013). Psychosine accumulation has been reported
to perturb lipid raft architecture, impede oligodendrocyte
differentiation, and cause aberrant cell signaling; however,
the precise mechanisms of cell death remain unclear (Giri
et al., 2006; Ballabio and Gieselmann, 2009; White et al.,
2009; Won et al., 2013).
Newly synthesized GALC is cotranslationally trans-
located into the endoplasmic reticulum (ER) and enters
the Golgi apparatus, where it is posttranslationally modi-
fied by N-linked glycosylation at four sites (Deane et al.,
2011; Fig. 1). Glycan side chains are further modified by
the addition of mannose 6-phosphate (M6P) groups that
are recognized by the cation-independent M6P receptor
(M6PR). The M6PR–GALC complex is transported
from the trans-Golgi network (TGN) to the endosomal
compartments. In the low-pH environment of the late
endosome, the M6PR–GALC complex dissociates, the
M6PR is recycled back to the TGN, and GALC is deliv-
ered to the lysosome (Gu et al., 2001; Huotari and Helen-
ius, 2011). Alternatively, GALC can be delivered to the
lysosome indirectly via secretion and reuptake by the
M6PR (Nagano et al., 1998). Only proteins that are cor-
rectly folded and stable can exit the quality control sys-
tems within the ER and traffic correctly to the lysosome.
After successful delivery to the lysosome, a loop on the
surface of GALC is cleaved, resulting in the detection of
50-kDa and 30-kDa bands by SDS-PAGE. However, this
cleavage event is not an activating step because the
uncleaved enzyme retains activity (Hill et al., 2013).
GALC has optimal catalytic activity at low pH and proc-
esses sphingolipid substrates in the acidic environment of
the lysosome. Nonenzymatic sphingolipid activator pro-
teins known as saposins are additionally required for the
degradation of sphingolipids by lysosomal hydrolases. In
rare cases, lack of functional saposin A can cause KD
(Spiegel et al., 2005; Table I).
THERAPEUTIC STRATEGIES FOR KD
Just as with many other LSDs, the molecular heterogene-
ity and poor correlation among genotype, phenotype, and
prevalence of CNS involvement pose a significant barrier
for successful therapeutic intervention for KD. Currently,
the only approved and available treatment option for
those affected with KD is hematopoietic stem cell trans-
plantation (HSCT; Krivit et al., 1998). However, its lim-
ited success, short therapeutic window, and high
associated risk highlight the still unmet clinical require-
ment for other viable treatment options (Siddiqi et al.,
2006; Duffner et al., 2009).
Enzyme replacement therapy (ERT) is an approach
commonly used to treat LSDs and is the current standard
of care for Gaucher’s, Fabry’s, and Pompe’s diseases as
well as for mucopolysaccharidoses (MPS) I, II, and VI
(Sands, 2014). However, the primary neurodegeneration
observed in KD requires the desired therapeutic to cross
the blood–brain barrier (BBB), and recombinant lysoso-
mal enzymes used for ERT are too large to achieve this.
The transient nature of ERT also requires weekly admin-
istrations of recombinant enzyme, which are expensive in
both time and resources. The recent advances made in
gene therapy provide a promising avenue for the treat-
ment of CNS-involved LSDs. Viral vectors such as AAV9
have been shown to cross the BBB for effective CNS
delivery in MPS III A and B (Foust et al., 2009; Fu et al.,
2011; Aronovich and Hackett, 2015). For KD, it has
been suggested that specific neuronal or glial tropisms
may be required in such viral vectors, and work with the
twitcher mouse model of KD is showing great promise
(Rafi et al., 2012). This is an exciting direction for new
therapeutic approaches for KD but is outside the scope of
this Review and has been well reviewed elsewhere (Haw-
kins-Salsbury et al., 2011; Nagabhushan Kalburgi et al.,
2013).
Substrate reduction therapy (SRT) is another
approach that has shown promise in treating LSDs such as
in type I Gaucher’s disease (Cox et al., 2000, 2003). By
decreasing the synthesis of primary substrate, SRT seeks
to target and diminish pathogenic substrate accumulation
and reduce lysosomal dysfunction as a result of decreased
load. However, because accumulation of the primary
Fig. 1. Processing and trafficking of GALC to the lysosome. GALC is
produced in the ER and glycosylated (Glyc-GALC) in the Golgi
apparatus (GA). Glycans modified with M6P groups are recognized by
M6PR. The M6PR-GALC complex is transported to the early endo-
somal (EE) compartment, and, in the low-pH environment of the late
endosome (LE), the complex dissociates. The M6PR is recycled back
to the GA, and GALC is delivered to the lysosome. GALC can also
be trafficked via the constitutive secretory pathway and delivered to
the lysosome via reuptake by the M6PR.
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substrate GalCer is not observed in KD, the benefits of
reducing substrate production in KD remain unclear.
CHAPERONE THERAPY FOR KD
GALC missense mutations are responsible for at least 40%
of known KD cases, and most of these are predicted to
disrupt the fold of the enzyme (Deane et al., 2011). Muta-
tions that result in improper enzyme folding mean that
these mutant enzymes are not able to escape the tight
quality control systems within the ER and are conse-
quently retained in the ER, where they are targeted for
degradation by ER-associated degradation (ERAD) or, in
some cases, incorrectly modified and subsequently
TABLE I. Glossary and Abbreviations
Abbreviation Commonly used names Description
Allosteric chaperone Non-active site chaperone A small molecule that modulates enzyme activity by
binding to a site other than the active site
a-Gal A a-Galactosidase A Lysosomal glycoside hydrolase, responsible for the
hydrolysis of terminal a-galactosyl moieties from
glycolipids including globotriaosylceramide; defi-
cient in Fabry’s disease
Azasugar Iminosugar A sugar derivative possessing a nitrogen atom in the
ring of the structure
b-Gal b-Galactosidase Lysosomal glycoside hydrolase, responsible for the
hydrolysis of b-galactosides; deficient in GM1
gangliosidosis and Morquio B disease
BBB Blood–brain barrier A highly selective, permeable membrane that pro-
vides a dynamic interface between the brain and
the circulatory system to protect the CNS
DGJ 1-Deoxy-galacto-nojirimycin; migalastat Nonalkylated azasugar; reversible competitive inhibi-
tor of a-galactosidase A
DNJ 1-Deoxynojirimycin Glucose configured azasugar
ERAD Endoplasmic reticulum associated degradation A cellular pathway that targets misfolded proteins in
the ER for subsequent degradation by the
proteasome
ERT Enzyme replacement therapy Therapeutic administration of an enzyme that is
defective or missing in a patient to alleviate the
effects of enzyme deficiency
GALC b-Galactocerebrosidase; galactosylceramidase Lysosomal glycoside hydrolase, responsible for the
hydrolysis of terminal b-galactosyl moieties from
glycolipids, including galactosylceramide, psycho-
sine, and lactosylceramide; deficient in KD
GalCer Galactocerebroside; galactosylceramide GALC natural substrate, a cerebroside consisting of a
ceramide with a galactose residue
HMG 6-Hexadecanoylamino-4-methylumbelliferyl-
b-D-galactopyranoside
Alkylated fluorogenic GALC substrate
HNG 2-Hexadecanoylamino-4-nitrophenyl-
b-D-galactopyranoside
Alkylated chromogenic GALC substrate
IGF Iso-galacto-fagomine; 4-epi-isofagomine Nonalkylated azasugar; galactosidase inhibitor
KD Krabbe disease; globoid cell leukodystrophy Lysosomal storage disorder caused by deficient b-
galactocerebrosidase; characterized by a progressive
neurodegenerative disease course
LSD Lysosomal storage disorder A family of rare inherited disorders caused by gene
mutations that disrupt lysosomal function; typically
characterized by abnormal accumulation of sub-
strate within the lysosome
NB-DNJ N-butyl deoxynojirimycin; miglustat; zaveska Alkylated glucose configured azasugar; ceramide glu-
cosyltransferase and GAA I and II inhibitor
PCT Pharmacological chaperone therapy A therapeutic strategy that uses small-molecule
inhibitors competitively and reversibly to bind and
stabilize the native conformation of misfolded
proteins
SRT Substrate reduction therapy Use of inhibitors to reduce the synthesis of substrates
such that residual degradative activity is sufficient
to prevent substrate accumulation
4MbDG 4-Methylumbelliferyl-b-D-galactopyranoside Water-soluble fluorogenic GALC substrate
4NbDG 4-Nitrophenyl-b-D-galactopyranoside Water-soluble chromogenic GALC substrate
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mistargeted within the cell (Fan, 2003). All such fates
lead to a loss of functional enzyme within the lysosome
and can elicit pathogenesis. In these cases, an alternative
treatment option currently being explored is pharmaco-
logical chaperone therapy (PCT). PCT relies on the use
of small molecules that specifically bind to and favor the
stabilization of the native conformation of misfolded pro-
teins, with the view of overcoming ER retention and
associated degradation and facilitating delivery of
enzymes to their required site of action (Ulloa-Aguirre
et al., 2004; Fig. 2). The ideal chaperone would bind to a
misfolded enzyme while it is synthesized in the ER, sta-
bilize the enzyme’s native conformation, and chaperone
the enzyme to its site of action in the lysosome. Here,
the chaperone would be displaced either by excess of
natural substrate or by pH effects, allowing the enzyme
to carry out its normal function. An advantage of using a
chaperone approach for lysosomal protein dysfunction is
the potential of harnessing the acidic environment of the
lysosome for chaperone dissociation, whereby chaper-
one–enzyme complexes can be stably transported to the
lysosome and then dissociate in the acidic conditions
(Suzuki, 2013). By assisting in the folding and stability of
mutant enzymes, the aim of PCT is to overcome lysoso-
mal enzyme deficiency by increasing the pool of func-
tional enzymes reaching the desired site of action
(Parenti, 2009).
The effectiveness of pharmacological chaperones
(PCs) is typically monitored by an increase in specific
hydrolase activity. Partial restoration of enzyme activity to
only 10% of wild-type (WT) levels has been reported to
provide sufficient enzyme activity to prevent disease in
LSDs (Kolter and Sandhoff, 1998). Therefore, even a
small increase in the amount of functional enzyme reach-
ing the lysosome could significantly attenuate disease pro-
gression (Leinekugel et al., 1992; Kolter and Sandhoff,
1998). Several Krabbe-associated missense mutations,
such as Y551S, G270D, and [I66M1 I289V] (Xu et al.,
2006; Tappino et al., 2010), have been reported to retain
residual enzyme activity. This, together with the low level
of enzymatic activity required to prevent disease in other
lysosomal disorders, identifies PCT as a promising
approach for KD (Schueler et al., 2004).
Penetration of the BBB is a major limitation for the
development of LSD therapy because 75% of described
LSDs have significant CNS involvement (Sands, 2014).
The properties of some small-molecule chaperones (low
molecular weight, low toxicity, and high bioavailability)
lend themselves well for the treatment of CNS pathology
because they have a greater capacity to cross the BBB
than enzymes. However, to achieve pharmacologically
significant CNS delivery, additional properties, such as
high lipid solubility, are also required (Pardridge, 2005).
In other LSDs, low-molecular-weight competitive
Fig. 2. Schematic representation of mutant protein fate within the cell
and the effect of small-molecule chaperones. In a healthy individual,
GALC is synthesized and correctly folded within the ER and subse-
quently transported to its site of action in the lysosome. Missense
mutations in GALC can cause an array of deleterious effects that lead
to KD. Missense mutations can affect the active site of the enzyme
and lead to catalytic deficiencies (A), cause posttranslational modifica-
tions that can mistarget GALC within the cell (B), or destabilize and
misfold GALC (C). Misfolded GALC is retained in the ER, where it
is targeted by ERAD and degraded, leading to loss of functional
GALC reaching the lysosome. Small-molecule chaperones can bind to
and stabilize GALC to overcome incorrect folding and escape degra-
dation, allowing successful transport to the lysosome.
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inhibitors that function as PCs to restore catalytic activity
of mutant enzymes have been identified (Suzuki et al.,
2009). Several of these candidates have led to successful
clinical translation, including but not limited to migalastat
(Amicus, Cranbury, NJ) for Fabry’s disease (Germain
et al., 2012), ambroxol (ExSAR, Monmouth, NJ) for
type I Gaucher’s disease (Zimran et al., 2013), and pyri-
methamine for GM2 gangliosidosis (Clarke et al., 2011).
Although these have provided proof of principle for PCT
as a viable treatment option for LSDs, the limited clinical
translation of PCT to date means that their utility as a
therapeutic is unclear, and, consequently, their long-term
efficacy remains uncertain. Many of these have been very
well reviewed elsewhere (Valenzano et al., 2011; Boyd
et al., 2013; Shayman and Larsen, 2014; Parenti et al.,
2015a,b), so this Review will focus on the development
of PCT specifically for KD.
IDENTIFYING CANDIDATE
CHAPERONES FOR KD
Multiple approaches have been explored to identify mole-
cules that exert a chaperoning effect on misfolded proteins
in LSDs. The most common approaches involve the use
of substrate mimics that are often targeted against the
active site of the deficient hydrolase, permitting specificity
and limiting off-target deleterious effects. Alternatively,
allosteric chaperones have been identified that are princi-
pally targeted away from the active site of the enzyme. As
such, this class of chaperone circumvents the problems
associated with enzyme inhibition often encountered
with substrate mimics. In a more general approach, cellu-
lar pathways often associated with misfolded proteins such
as ERAD and proteostasis have been targeted to promote
general protein folding. This latter approach has the
potential to target the secondary changes that often con-
tribute to the complex nature of LSDs and may, in part,
address the mutation-dependent effects often observed
with chaperones in heterogeneous genetic disorders. Sev-
eral of these approaches have been used for the identifica-
tion of GALC candidate chaperones for KD and are
reviewed here.
Substrate Mimics
Chaperone molecules used for the correction of
misfolded proteins in LSDs are often active-site-specific
competitive inhibitors. Targeting the active site of the
deficient hydrolase allows enhanced specificity, reducing
the risk of off-target effects, and can limit inhibitory
action on other, related enzymes (Butters et al., 2005).
Azasugar derivatives (also referred to as iminosugars) are
structural analogs of the sugar moieties on sphingolipid
substrates; as such, they make up a family of potent glyco-
sidase inhibitors and have been widely explored as candi-
date chaperones for LSDs (Fan, 2007). As well as being
highly soluble, azasugars have excellent biodistribution
and low toxicity and have been pursued as a promising
class of active-site-directed chaperone (Mellor et al.,
2004; Treiber et al., 2007; Horne et al., 2011). One of
the first to be described, 1-deoxygalactonojirimycin
(DGJ; migalastat), illustrates the potential of azasugars as
chaperone candidates for LSDs. DGJ is an inhibitor of a-
galactosidase A (a-gal A), the defective enzyme in Fabry’s
disease and has subsequently reached phase III clinical tri-
als (Fan et al., 1999; Guce et al., 2011; Germain et al.,
2012; Ishii, 2012).
In a recent study, a series of azasugar-based galacto-
side mimics was designed, synthesized, and evaluated for
their inhibitory effect on GALC (Biela-Banas et al.,
2014). To assess specificity for GALC, these studies were
carried out alongside the related lysosomal enzymes a-gal
A and b-galactosidase (b-gal). Total leukocyte sonicate
was used as the source of enzyme for these assays, and
specificity of inhibition was determined through use of
the substrate molecules tritiated GalCer for GALC, 4-
methylumbelliferyl (4MU)-b-D-galactopyranoside
(4MBDG) for b-gal, and 4MU-a-D-galactopyranoside
for a-gal A. Chaperone suitability was determined by the
percentage inhibition conferred by each of the tested
molecules on GALC at lysosomal pH 4 compared with its
effects on a-gal A and b-gal.
This study demonstrated several important features
of the azasugar candidates critical to their function as
GALC inhibitors. First, by testing 1-C-alkyl imino-L-ara-
bitols (Fig. 3, A), the 5-CH2OH group (marked by an
asterisk) was shown to be an essential constituent for both
a-gal A and b-gal inhibition, supporting previous obser-
vations (Bernotas et al., 1990). Second, it was demon-
strated that the 1-C-alkyl imino-D-galactitols (as with
DGJ; Fig. 3, B) were more potent inhibitors of a-gal A
than of the b-gals, whereas the 1-N-iminosugar series
(Fig. 3, C) was found to be the most potent inhibitor of
the b-gals. This critically highlights the importance of the
position of the nitrogen atom in the azasugar ring for
specificity between a- and b-gals. Although 4-epi-
isofagomine (also known as iso-galacto-fagomine; IGF) was
identified as a GALC inhibitor and conferred the greatest
inhibition on the b-gals, its inhibitory effect on b-gal
identifies a lack of specificity that may compromise its
potential as a KD therapeutic. However, Biela-Banas et al
propose that modifications of IGF may result in similar
inhibition with increased GALC specificity. Although
these findings highlight the subtleties in the azasugar ring
architecture that are required for specificity and inhibi-
tion, an understanding of each compound’s stabilizing
effect on GALC at both lysosomal and ER pH (represent-
ing the desired cellular conditions of initial chaperone
binding) would be beneficial, given that it is widely
known that binding can vary greatly between these two
cellular environments (Lieberman et al., 2009).
By targeting the active site of the enzyme, chaper-
ones can be rationally designed to enhance specificity.
Hill et al. (2015) used insights gained from GALC struc-
tural data as an atomic framework to design and charac-
terize a series of azasugar derivatives to serve as GALC-
specific candidate chaperones. Six different azasugars were
tested, including the nonalkylated azasugars DGJ and IGF
(Fig. 3, B, C); a related hydrazine aza-galacto-fagomine
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(AGF) possessing two nitrogen atoms in the sugar ring
equivalent to those in both IGF and DGJ; a five-
membered pyrrolidine derivative, dideoxy-imino-lyxitol
(DIL; Fig. 3, D); a d–lactam derivative, iso-galacto-
fagomine lactam (IGL; Fig. 3, E); and a bicyclic nortro-
pane, deoxy-galacto-noeurostegine (DGN; Fig. 3, F).
Inhibitory kinetics were determined by using purified
GALC for each of these candidates at pH 4.6, the optimal
Fig. 3. Different classes of PCT molecules identified for KD. Top: Chemical structure of the pri-
mary GALC substrate b-galactosylceramide illustrating atom numbering for the glycosyl moiety.
Bottom: Classifications and chemical structures of small molecules identified as potential PCT can-
didates for KD. Specific azasugar molecules include 1-C-alkyl imino-L-arabitols (A); 1-C-alkyl
imino-D-galactitols, e.g., DGJ (B); 1-N-iminosugars, e.g., IGF (C); DIL (D); IGL (E); and
DGN (F).
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pH for GALC activity. With the exception of the bridged
azasugar DGN, all of those tested exhibited significant
competitive inhibition of GALC. This study was
extended beyond inhibition to illustrate the ability of
each of the molecules to confer stabilization of GALC in
vitro and to show that the observed stabilization is directly
correlated with binding affinity. IGF and AGF were the
most potent inhibitors (Ki 3806 26 nM and 6306
53 nM, respectively) and conferred the highest degree of
global stabilization, providing the basis for using these as
optimal scaffolds. GALC stabilization was measured by
thermal denaturation at two different pH values repre-
senting the cellular environments of the lysosome
(pH 4.6) and ER (pH 7.2). All but one test compound
(DGN) increased the stability of WT enzyme under both
conditions in a dose-dependent manner. However, stabi-
lization of GALC was greater at low pH than at neutral
pH, a suboptimal feature for a PC. To confirm specificity,
glucose-configured 1-deoxynojirimycin (DNJ) was tested
and did not stabilize or change the melting temperature of
GALC. Crystallographic studies showed that each of the
candidate compounds directly bound in the active site of
GALC. Analysis of the binding interactions revealed the
critical role of the interaction between the ring nitrogen
and the side chain of the active site nucleophile (E258) as
well as the importance of the ring pucker. This study
reinforces the greater potency of IGF over other azasugar
derivatives and highlights the specific characteristics of
azasugars required for optimal binding specificity and
affinity. However, this study also reveals that, because of
the electrostatic nature of the interaction, azasugar mole-
cules bind more tightly at lysosomal pH than they do at
neutral pH. Thus, PCT molecules that contain nitrogen
in the ring have the advantage of high-affinity binding
but have to overcome the tighter binding at low pH to
function as efficient chaperones. In these cases, rather
than exploiting the acidic pH of the lysosome, the success
of these molecules may depend on the ability of excess
substrate to compete for binding to the active site.
Another molecule resembling the natural substrate
of GALC is N-ocytl-4-epi-b-valienamine (NOEV; Fig.
3), a potent b-gal inhibitor and potential chaperone ther-
apeutic for GM1-gangliosidosis (Suzuki et al., 2007). Hos-
sain et al. (2015) tested NOEV as a candidate chaperone
for mutant GALC, with an emphasis on those mutations
attributed to late onset forms of KD. To determine
whether NOEV could confer resistance to heat denatura-
tion, enzyme activity was measured in lysates from
GALC-transfected cells that had been incubated at 48 8C
in the presence and absence of NOEV. After heat treat-
ment, WT GALC lysates retained higher activity in the
presence of NOEV, suggesting that this molecule
increases the stability of GALC. However, lysates from six
different mutant forms of GALC did not display signifi-
cant stabilization with NOEV. An alternative measure of
successful chaperoning of GALC to the lysosome is to
monitor the appearance of the cleaved form of GALC
that occurs upon delivery to the lysosome. For several
GALC variants, including G270D, G569S, and
[I66M1 I289V], NOEV treatment of GALC-transfected
cells resulted in an increase in GALC processing, suggest-
ing that these mutant forms were successfully trafficked to
the lysosome. Unfortunately, the observed increase in
cleaved product was not detectable in patient cells, and
only one patient sample showed a statistically significant
increase in enzyme activity following NOEV treatment.
As expected from its chemical structure and ability to
inhibit GALC, docking model analysis predicted that
NOEV would bind the GALC active site. However, it is
unclear how its affinity for GALC compares with other
azasugars because NOEV lacks a nitrogen atom in the
equivalent position shown to be required for high-affinity
binding of the nonalkylated azasugars. However, although
the lack of nitrogen in the ring may lower its affinity for
GALC, this feature may be an advantage in terms of
exploiting the acidic conditions in the lysosome for chap-
erone dissociation. Predictions of binding free energy of
NOEV to b-gal at pH 5 and pH 7 suggest that the affinity
was lower at pH 5 (Suzuki et al., 2009). This may also be
the case for GALC and may prove to be a greater advant-
age than high-affinity binding alone. Although NOEV
has been identified as a chaperone for GM1-gangliosido-
sis, Hossain et al. (2015) did not directly compare the
potency of NOEV as a chaperone for GALC with the
lysosomal b-gal responsible for GM1-gangliosidosis and,
as such, the specificity for use as a Krabbe therapeutic
remains unclear.
Allosteric Chaperones
To date, the search for new candidate PCT mole-
cules for KD has focused on the ability of small molecules
to inhibit GALC. Although active-site-directed chaper-
ones confer specificity, the counterintuitive use of
enzyme inhibitors is often criticized because the chaper-
one is, by nature, a competitive inhibitor of its intended
enzyme target. The requirement to balance between
chaperoning activity and enzyme inhibition is a potential
barrier to their therapeutic efficacy. To overcome prob-
lems associated with active-site-directed inhibitors, allo-
steric chaperones have been explored as an alternative
chaperone strategy. By binding to an allosteric site, the
functional state of the enzyme may be rescued without
competitive inhibition.
Two molecules that were originally identified as
weak inhibitors of GALC may confer some chaperoning
activity via allosteric mechanisms rather than by active site
binding. a-Lobeline, a simple alkaloid, has been tested in
two separate studies to identify candidate GALC chaper-
ones (Fig. 3). First reported by W.C. Lee et al. (2010), a-
lobeline was identified as a weak GALC inhibitor by an
enzyme activity screening method. Those molecules that
inhibited GALC function by more than 25% were
selected, and dose–response assays were used to confirm
and validate the initial results. At the highest concentra-
tion of a-lobeline tested (240 lM), both intra- and
extracellular activity of the Krabbe-associated hyperglyco-
sylation mutation D528N increased in a neuronal cell
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line. The high dose of a-lobeline required to cause an
observed chaperoning effect is concerning because it has
been suggested that application of more than 20 lM of
compound will not easily pass the ER barrier (Butters
et al., 2005). Furthermore, compounds at such high doses
may elicit unwanted side effects elsewhere and are there-
fore not attractive leads for pharmaceutical development.
Although other Krabbe-associated mutations were tested
(I234T and L629R), only D528N showed any rescue of
function. However, given the number of missense muta-
tions that exist in KD, those tested constitute only a small
fraction of causative mutations and may not be true repre-
sentations of the percentage of a-lobeline-responsive
GALC candidates. Despite the use of image-based immu-
nostaining to localize GALC and characterize the mutants
used in this study, immunolabeling and lysosomal GALC
processing were not used as readouts of compound effi-
cacy but might have proved useful for better understand-
ing the effect of a-lobeline on the cellular localization of
mutant GALC.
Just as in W.C. Lee et al. (2010), Berardi et al.
(2014) used an enzymatic assay to screen a series of mole-
cules, including azasugar analogs, for inhibitory effects on
GALC. Their initial screen did not identify any com-
pounds with significant inhibition of GALC activity at
the test concentration of 400 lM; despite this, studies
were continued with two test compounds, a-lobeline
(identified previously) and 30407-trihydroxyisoflavone
(Fig. 3). To test the effectiveness of these candidate chap-
erones, fibroblast cell lines carrying a range of clinically
relevant missense GALC mutations (G537R,
[E114K1N279T], and G41S) were treated with either
a-lobeline or 30407-trihydroxyisoflavone for 72 hr at 50,
100, and 200 lM before GALC activity was measured
from whole-cell lysates. In the cell line homozygous for
the G537R mutation, a-lobeline increased GALC activ-
ity at 50 and 100 lM, with no further increase in activity
at 200 lM, whereas increasing concentrations of 30407-
trihydroxyisoflavone increased GALC activity. Both a-
lobeline and 30407-trihydroxyisoflavone increased GALC
activity in the cell line expressing both E114K and
N279T mutations, with the greatest effect observed at
lower concentrations of both candidate chaperones. Simi-
larly, both a-lobeline and 30407-trihydroxyisoflavone
increased GALC activity in the cell line homozygous for
the G41S mutation. For all these assays, GALC activity
was compared with untreated cells but was not compared
with normal WT GALC activity levels. Because each
mutant cell line possessed different levels of residual
GALC activity, it remains unclear which treatments
brought activity up to a significant proportion of WT lev-
els. Two late-onset mutations not predicted to affect the
fold of GALC were additionally analyzed, and no change
in GALC activity was observed with either of the test
compounds. This underscores the requirement of identi-
fying the specific GALC variants that result in protein
misfolding for successful testing and development of
PCTs. This, alongside the difference in compound effi-
cacy on those mutations tested, signifies the requirement
for a tailored and individualized approach to chaperone
therapy.
Both compounds explored showed weak GALC
inhibition at pH 5.2, and docking analysis identified nine
different potential binding sites on GALC, with only one
site overlapping with that of the natural substrate. Thus,
although these molecules were selected based on their
capacity to inhibit GALC, the likely mechanism by which
these molecules may function as PCs is via allosteric bind-
ing. One of the two molecules tested in this study, 30407-
trihydroxyisoflavone, has been shown to possess inhibi-
tory activity against other cellular enzymes, including
cyclin-dependent kinases, phosphatidylinositol 3-kinase,
xanthine oxidase, and macrophage migration inhibitory
factor (Orita et al., 2001; Park et al., 2008; D.E. Lee
et al., 2010). This, combined with the relatively low
binding energies reported from the docking studies, raises
some concerns with respect to the specificity of this mole-
cule as a GALC chaperone.
Cell-based high-throughput screens with chemical
libraries have also been undertaken to identify small-
molecule chaperones suitable for KD. Ribbens et al.
(2013) successfully automated and optimized a highly sensi-
tive fluorimetric assay for the identification of GALC
inhibitors in a cell line expressing GALC mutation
G270D, associated with late-onset forms of KD. Unfortu-
nately, none of the 1,280 molecules tested in this study
showed any statistical improvement in GALC activity, and
toxic effects confounded many of those that were tested.
The extensive toxicity observed highlights a caveat of test-
ing chaperones that are not directed against the active site
because they can be confounded by off-target and often
detrimental effects. Moreover, many of the compounds
included in the screens had not previously been indicated
to cross the BBB. In light of these observations, for initial
screening purposes, if not performing active-site-targeted
drug design, it would be reasonable to repurpose approved
drugs with a known ability to cross the BBB rather than
screening large libraries of drugs that may never be relevant
for CNS diseases. The use of preexisting drugs (such as
NOEV and a-lobeline) as candidate GALC chaperones is
advantageous because many of their characteristics, such as
low toxicity and the ability to penetrate the BBB, are
already well defined and are critical characteristics when
targeting neurological symptoms prominent in KD.
Although this study provides a useful developmental
approach for applying high-throughput methodologies,
currently it allows only for single mutation testing. It
does, however, allow for the possibility of identifying
more general proteostasis regulators that promote
enhancement of residual GALC–G270D activity via
diverse mechanisms that may be missed in conventional
rational drug design strategies.
METHODS FOR MONITORING THE
EFFECTIVENESS OF CHAPERONES
Just as with other LSDs, the effectiveness of chaperone
molecules is commonly measured only by their capacity
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to increase the level of enzyme activity above a prede-
fined threshold in treated cells. In the case of KD, enzyme
activity does not correlate well with the severity of dis-
ease, meaning that conclusions drawn on activity alone
are not as compelling as those studies that can illustrate
increased stabilization of GALC, detection of cleaved
GALC (indicating successful delivery to the lysosome),
improved lysosomal localization, or reduced accumulation
of psychosine (Wenger et al., 2000; Duffner, 2009).
However, these alternative measures are considerably
more difficult to carry out and are not easily amenable to
high-throughput approaches.
As outlined by Valenzano et al. (2011), it is essential
to meet a number of key criteria to assess correctly the
efficacy of a chaperone on its intended enzyme target.
First, it is imperative to show that the observed effects are
directly facilitated by the chaperone, commonly shown
by stabilization or inhibition of either WT or mutant
enzyme. Second, it is important to measure the effect of
the chaperone on the level of total enzyme within the
cell; for example, protein levels can be directly monitored
with Western blotting. Finally, from the principle of
chaperone therapy, candidate molecules should not only
bind and stabilize GALC but also correct aberrant local-
ization. To measure the ability of a chaperone to promote
lysosomal trafficking, cell-based methods such as subcellu-
lar fractionation and image-based subcellular location can
be carried out. This latter approach has the benefit of
simultaneously monitoring the target enzyme and
organelle-specific markers as well as the potential to be
adaptable for high-throughput screening methodologies
(Starkuviene and Pepperkok, 2007; Zanella et al., 2010).
For those missense mutations that retain residual
activity but are mislocalized, chaperones may facilitate the
transport of functional enzyme to its desired site of action
within the lysosome, without directly increasing its activ-
ity. Therefore, although it is important to know whether
a mutation retains activity for the success of a PCT candi-
date to be explored, it is also essential to understand how
specific GALC mutations affect localization and function-
ality within the cell.
Although enzyme activity has limitations as a mea-
sure of chaperone efficacy, it is a commonly used
approach that provides a relatively clear functional read-
out that is straightforward to perform. Because of its wide
application, it is important to discuss a number of caveats
to this approach that must be considered when analyzing
activity data.
Substrate Selection
In the work published to date, a range of different
substrates has been used to monitor GALC activity,
including tritiated GalCer (Biela-Banas et al., 2014), alky-
lated fluorogenic and colorimetric substrates such as 2-
hexadecanoylamino-4-nitrophenyl-b-D-galactopyranoside
(HNG; W.C. Lee et al., 2010) and 6-hexadecanoylamino-
4-methylumbelliferyl-b-D-galactopyranoside (HMG;
Ribbens et al., 2013; Berardi et al., 2014; Hossain et al.,
2015), and water-soluble fluorogenic and colorimetric
substrates such as 4NBDG (Hill et al., 2015) and 4MBDG
(Martino et al., 2009).
Unfortunately, the activities determined with differ-
ent substrates cannot be directly compared, making useful
comparisons among studies impossible. Furthermore, the
specificity of these substrates may differ and can be highly
dependent on the assay conditions. For example, the con-
centration of taurocholate and oleic acid in the enzyme
activity buffer is critical for the alkylated substrate HMG
to establish specificity for GALC vs. b-gal. Importantly,
at high concentrations of taurocholate, HMG shows no
specificity for GALC highlighted by the observation of
equivalent enzyme activity in control and twitcher mouse
samples (Wiederschain et al., 1992).
Enzyme Source
The source of enzyme for most activity assays is
whole-cell lysate. Because many of these assays are often
performed without any purification or enrichment steps,
considerable activity is likely to be contributed by other
galactosidase enzymes. Although this can be controlled, if
the proportion of activity contributed by GALC is small
and, thus, there is a large background correction the
effectiveness of chaperone molecules may be under- or
overestimated. Related to this, GALC has a very specific
pH-dependent activity profile, so it is critical that the
activity be measured within the optimal pH range of the
enzyme (pH 4.3–5.3; Hill et al., 2013). Outside of this
pH range, GALC activity is significantly reduced such
that enzyme activity measurements from whole-cell
lysates at suboptimal pH possess essentially no activity
from GALC. An additional consideration for assays con-
ducted on whole-cell lysates is the difficulty of distin-
guishing among protein localized in different subcellular
compartments, such as in the ER or endocytic/lysosomal
compartments. The goal of PCT is to ensure that active
enzyme is delivered to the required site of action in the
lysosome, and measures of whole-cell activity cannot ver-
ify the localization of this activity. In support of this,
activities measured from samples enriched for the lysoso-
mal fraction have shown a better correlation with disease
severity than had been previously observed (Shin et al.,
2016). This finding provides a good foundation for
improved reliability for future activity measurements.
Together with Wenger et al. (2014), who showed that in
vitro activity assays might not give a true representation
of the enzyme activity in relevant tissues such as the nerv-
ous system, these indicate that, although activity assays
from whole-cell lysates provide a reasonable first approxi-
mation of the effectiveness of any therapeutic, they do
not provide information on either the cellular location or
the functionality of the chaperone. Therefore, it is impor-
tant that alternative measures of efficacy, such as restored
GALC processing, lysosomal localization, or reduced psy-
chosine accumulation, be carried out for a more robust
identification of effective chaperone molecules.
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GALC Quantification
To distinguish between absence of protein and inac-
tive protein, it is important to be able to estimate the
amount of GALC present in an activity assay. This is
especially important when comparing relative activities
among different mutations or between PCT-treated and -
untreated cells. Accurate quantification of very small
amounts of GALC is very challenging, not just because of
detection limits in techniques such as Western blotting
but also because of the presence of both full-length and
cleaved forms of GALC within cells. Moreover, a critical
consideration for any activity assay performed on drug-
treated cells is the addition of a washout prior to activity
measurement to prevent the carryover of any residual
PCs. However, the length of washout required is depend-
ent on the half-life of the enzyme, and, in many cases,
this differs between WT and mutant enzymes.
IDENTIFYING CANDIDATE
MUTATIONS FOR PCT
The development of successful PCT for KD relies not
only on the robust identification of candidate chaperones
but also on the identification of those mutations that will
respond best to treatment. PCT is not a one-size-fits-all
therapy and requires an understanding of the mechanism
of the defect caused by specific mutations to allow the
best chance for successful treatment. More than 110
mutations have been identified in the GALC gene that
affect GALC mRNA processing or cause deletions, frame
shifts, and missense mutations (Rafi et al., 1996; Wenger
et al., 1997; De Gasperi et al., 1999; Lee et al., 2006; Tap-
pino et al., 2010). It is evident that, for those cases of KD
resulting from the common 30-kb deletion within the
GALC gene or arising from mutations in cofactors such
as saposin A, PCT will not be an appropriate therapy
(Luzi et al., 1995; Rafi et al., 1995; Spiegel et al., 2005).
Instead, PCT should be targeted at those mutations that
result in defective cellular localization resulting from
compromised enzyme stability or folding. The nature and
location of the amino acid substitution will play a critical
role in determining whether a variant is likely to affect
folding and, therefore, respond to PCT.
Within the subset of missense mutations, aberrant
GALC function may result from catalytic inactivity, post-
translational modifications, misfolding, or premature deg-
radation. Structural data can provide a framework for
predicting the mechanisms of certain mutations to help
identify those mutations that may be responsive to PCT.
Missense mutations that lie within the active site of
GALC, such as the R380W mutation (Fig. 4), directly
disrupt the interactions between enzyme and substrate,
critically affecting enzyme activity but not folding (Hill
et al., 2013; Spratley, et al., 2016). The R380W mutation
thus causes a severe, early-onset form of KD because of
catalytic inactivity (Wenger et al., 1997). Enzyme stabili-
zation by a PC cannot overcome this type of defect, so
mutations of critical active site residues will not respond
to PCT. It is important to recognize that this mechanism
of loss of GALC activity is distinct from those caused by
folding defects.
It is likely that some chaperones will exhibit stabiliz-
ing effects in a highly mutation-specific manner. This may
be the case with the GALC mutation D528N, which
showed enhanced activity when treated with a-lobeline
(W.C. Lee et al., 2010). The mutation of D528 to aspara-
gine (N) altered the posttranslational modification of
GALC by introducing an additional N-linked glycan.
Because D528 lies on a surface loop within the lectin
domain, the introduction of an extra glycan may not have
caused significant misfolding (Fig. 4). Thus, for this muta-
tion, the chaperoning effect conferred by a-lobeline might
have been specific to the newly introduced glycan. In sup-
port of this, it was observed that a-lobeline does not confer
any increase in thermal stability to WT GALC and may
also explain why it did not have a chaperoning effect on
the other GALC variants tested (W.C. Lee et al., 2010;
Hill et al., 2015).
Identifying the best candidates for PCT is challeng-
ing, even with predictions made possible with reference
to the GALC atomic structure. A large proportion
(80%) of the identified KD missense mutations are bur-
ied deep within the structure and are predicted to cause
GALC misfolding (Deane et al., 2011). Because all three
domains of GALC contribute to the formation of the
active site pocket, it is possible that even localized mis-
folding of any region could perturb enzyme activity
resulting from disruption of the active site architecture
(Deane et al., 2011). Therefore, those mutations that have
been identified as catalytically inactive but are not them-
selves localized close to the active site may benefit from
overall enzyme stabilization conferred by a chaperone and
should not be discounted as targets for PCT. One exam-
ple of a GALC mutation that is buried in the structure
and lies far from the active site is L618S (Fig. 4). This
mutation is found within the lectin domain, has been
shown to have very low activity, and is implicated in late-
infantile- and adult-onset KD (Furuya et al., 1997; Satoh
et al., 1997; Xu et al., 2006). Although mutation of L618
to serine (S) does not introduce a significantly larger side
chain that might cause steric clashes, it alters the hydro-
phobic nature of this side chain and, thus, alters the local
interactions in the lectin domain. The mutations responsi-
ble for later-onset KD, such as L618S and G270D, may
possess subtler misfolding defects than the early-onset var-
iants and, therefore, may respond better to PCT. There-
fore, these might turn out to be important variants to
consider in high-throughput screening of new chaperone
candidates. Correct identification of misfolding mutations
in KD patients will identify suitable KD candidates for
PCT. However, it is likely that only a fraction of missense
mutations responsible for GALC misfolding may be ame-
nable to PCT, exemplified by the mutation-specific
effects observed for PC candidates tested to date.
An important consideration when characterizing
mutations is the wide range of GALC activity reported in
noncarrier and carrier individuals (Harzer et al., 2002).
This has, in part, been attributed to polymorphisms present
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in the normal allele of the GALC gene that contribute to
lower-than-normal GALC activity and can confound diag-
nosis and analysis of therapeutic efficacy (Furuya et al.,
1997; Wenger et al., 2014; Shin et al., 2016). The G270D
mutation, commonly associated with late-onset forms of
the disease, is often found alongside the common polymor-
phism I546T (found in 35–45% of the population);
together, they show lower GALC activity than when
expressed on their own (Wenger et al., 2014). Likewise, it
has been shown by Shin et al. (2016) and Spratley et al.
(2016) that the combination of certain cispolymorphisms
and disease mutations can significantly reduce the activity
and trafficking of GALC. The full impact of known poly-
morphisms on KD prognosis and therapeutic intervention
has yet to be elucidated but must be taken into considera-
tion when characterizing and identifying candidate GALC
mutations. Alongside the polymorphic background of each
Krabbe variant, heterogeneity makes for complex analysis
of disease phenotype and can also confound interpretation
of chaperone effects. For heterozygous KD mutations such
as [E114K1N279T], determining the chaperone-
responsive mutation is difficult, and it is currently unclear
whether the presence of another mutation alters a chaper-
oning effect (Grabowski, 1997).
Validating Candidate Mutations
After a suitable mutation has been identified as a tar-
get for PCT, ongoing validation in an appropriate model
system should be pursued. However, chaperones that
appear mutation specific are currently not easily explored
in living models of the disease. Confounding this is the
small Krabbe patient population, which means that patient
tissue samples are difficult to obtain, especially in the early
stages of novel chaperone development. Most preliminary
testing is, therefore, conducted in cell lines expressing
clinically relevant mutations. Although this has been
shown to be effective for initial screening, it may not
translate directly to the clinical phenotype.
Several spontaneous models for KD exist in a num-
ber of species, including mouse (Suzuki and Suzuki,
1995), dog (Victoria et al., 1996), and rhesus monkey
(Baskin et al., 1998). Among these, the twitcher mouse is
the most commonly studied. However, as a mimic of the
30-kb deletion, the lack of GALC is inappropriate for
analysis of PCT efficacy for missense mutations (Kobaya-
shi et al., 1980; Suzuki and Suzuki, 1995). The GALCtwi-5j
mouse has a spontaneous missense mutation in GALC
equivalent to the human GALC substitution E130K
responsible for a severe infantile form of the disease and
Fig. 4. KD-associated mutations of GALC. Three residues that are
mutated in KD are highlighted on the structure of GALC (PDB ID:
3ZR6). The structure is colored according to domain (TIM barrel,
blue; b-sandwich, red; lectin domain, green), and the disulfide bond
(yellow) and calcium ion (gray) are illustrated as spheres. The galactose
product (pink sticks) is shown in the GALC active site. For each
mutation, the closeup view (inset) shows the relevant residue as sticks
(oxygen atoms, red; nitrogen atoms, blue) and the surrounding region
of the structure that would be affected by the mutation.
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represents a more appropriate model for drug screening
(Tappino et al., 2010; Potter et al., 2013). Although sponta-
neous model systems provide tools for investigating patho-
genesis and evaluating therapeutic approaches, the ability to
introduce specific clinical mutations into appropriate model
systems quickly and effectively will allow more effective
evaluation of potential therapeutics and validation of PCT
candidates for KD. This has been made feasible by advances
in gene editing techniques such as CRISPR-cas, zinc-fin-
ger nucleases, and transcription-activator-like effector
nucleases, all of which provide strategies for achieving site-
specific gene manipulations to accelerate the generation of
new mutation-specific models (Cui et al., 2011; Yang
et al., 2014; Sommer et al., 2015). Although these techni-
ques have been shown to be effective in generating
mutation-specific mouse models and to have the potential
to extend into larger animal models to study the neurode-
generative aspects observed in KD, the high associated cost
and time to generate such models are still limiting (Inui
et al., 2014; Tu et al., 2015). To overcome this, studies of
GALC in zebrafish (Danio rerio) provide an affordable alter-
native platform in which to evaluate therapeutic approaches
effectively (Zizioli et al., 2014). Generation of site-specific
mutations can be carried out efficiently with the gene-
editing techniques mentioned above and are well estab-
lished in this model system (Huang et al., 2012; Hwang
et al., 2013).
COMBINATION THEREAPY: ENHANCING
FUTURE THERAPIES
PCs have shown great potential when used in combina-
tion with other therapeutic approaches. In LSDs for
which enzyme replacement therapies are available, syner-
gistic effects have been observed when PC candidates are
combined with recombinant enzymes (Parenti, 2009;
Lukas et al., 2015). This combination approach is known
as enzyme enhancement therapy and has the advantage that
PCs are used with the exogenous WT enzyme, and, con-
sequently, the effects observed are independent of the
mutation carried by the patient and may translate to
improved numbers of responsive patients. Although the
use of ERT in CNS-involved LSDs such as KD is limited
to the management of associated peripheral dysfunction
(Platt, 2014), it was shown in the twitcher mouse model
of KD that both peripheral and cerebral administration of
GALC significantly increased life span, improved motor
function, and reduced psychosine accumulation (Lee
et al., 2005; Qin et al., 2012). Although ERT has not yet
been clinically developed for KD, a major therapeutic
goal is the development of strategies for improving deliv-
ery of peripherally infused enzyme to the brain and the
CNS. Several approaches are currently being developed
in related diseases to facilitate the transport of enzyme
across the BBB (Zhang and Pardridge, 2005; Grubb et al.,
2008; Osborn et al., 2008; Gabathuler, 2010). Future
development of ERT for KD will benefit from the identi-
fication of stabilizing PC molecules.
PC molecules may enhance ERT by several mecha-
nisms, including increasing the half-life and the biodistri-
bution of administered enzyme. Poor biodistribution is a
significant obstacle for ERT, and, even if the enzyme
reaches the appropriate tissue, it has been suggested that
recombinant enzymes may be relatively unstable when
exposed to suboptimal environments on transit to the
lysosome (Schoser et al., 2008; Benjamin et al., 2012).
Coadministration of recombinant enzyme and active-site-
directed chaperones N-butyl deoxynojirimycin (NB-
DNJ) and isofagomine used in Pompe’s and Gaucher’s
disease, respectively, showed improvement in stability,
lysosomal trafficking, maturation, and intracellular activity
(Shen et al., 2008; Porto et al., 2009). Similar synergistic
effects on a-glucosidase (GAA), the defective enzyme in
Pompe disease, were observed with the allosteric chaper-
one N-acetlycysteine (NAC; Porto et al., 2012). ERT is
often used in Pompe’s disease but has shown limited ther-
apeutic efficacy in some patients (Porto et al., 2009).
NAC improved the stability of GAA as a function of pH
and temperature, with no effect on activity. As an alloste-
ric binder, NAC does not interact with the catalytic
domain and is therefore not a competitive inhibitor of the
enzyme. Furthermore, coadministration of GAA and
NAC improved GAA activity in a dose-dependent man-
ner and additionally improved correction of GAA defi-
ciency in patient cell lines with mutated GAA. Although
Pompe’s disease is primarily a systemic disease, these
proof-of-principle experiments indicate the potential use
for chaperones as stabilizing agents for administered
recombinant enzymes used in ERT. The combination of
NAC and DNJ (an active-site-directed chaperone) gave
the highest thermal stability of GAA. Because these two
small molecules have different chaperone profiles, this
may overcome some of the mutation-specific effects and
the complexity observed in compound heterozygous
patients.
Moreover, it has been observed that enzymes used
in ERT can destabilize while in storage, and, in response
to the administered unfolded protein, a hypersensitive
immune reaction can be triggered (Maas et al., 2007).
Therefore, inclusion of a chaperone may limit protein
unfolding by stabilizing the ERT enzyme in storage,
increasing efficacy and limiting adverse effects observed in
ERT. Thus, in addition to their role in rescuing destabi-
lized mutant enzymes that are retained in the ER, the
small molecules reviewed in this work may enhance the
effectiveness of recombinant WT enzymes in future ERT
development programs for KD.
Currently, the only available treatment for KD is
HSCT, which slows the progression of disease when per-
formed before the onset of symptoms (Escolar et al.,
2005). For the infantile form of KD, initiating treatment
sufficiently early is highly challenging. It is possible that
small molecules (such as those reviewed here) could be
administered before the onset of KD symptoms to help
lengthen the therapeutic window for HSCT and enhance
the rate of success.
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A Bifunctional Role for Chaperone Molecules
In the case of PCT molecules that mimic the sub-
strate, such as azasugar derivatives, it is conceivable that
their effects are bifunctional. The similarity of these PCT
molecules to the glycan on the substrate means that, in
addition to their ability to bind their respective hydro-
lases, they also have the potential to bind the glycan-
synthesizing enzyme. For example, miglustat (also known
as zaveska) is NB-DNJ, an alkylated glucose analog of
DGJ, and is used for the treatment of adult patients with
mild to moderate type I (nonneuropathic) Gaucher’s dis-
ease. Miglustat is thought to function primarily as an SRT
by inhibiting the glucosylceramide synthase (Cox et al.,
2000, 2003; Moyses, 2003). However, because this mole-
cule also binds to the active site of acid b-glucosidase and
stabilizes the enzyme, it may also function as a PCT
(Brumshtein et al., 2007; Abian et al., 2011). Similarly,
migalastat is the therapeutic name for DGJ and has shown
effectiveness as a PCT for Fabry’s disease by stimulating
the activity of a-galactosidase and decreasing accumula-
tion of substrate in female patients (Giugliani et al., 2013).
Alkylated derivatives of DGJ have been identified as
inhibitors of glycolipid biogenesis, so it is possible that
some PCT molecules also function as SRTs by inhibiting
the relevant synthetic enzyme (Platt et al., 1994). This
potential for PCT molecules to function in other
pathways that ameliorate disease may also be relevant for
some molecules that do not function by binding the
active site. For example, isoflavones similar to 30407-
trihydroxyisoflavone described by Berardi et al. (2014)
have been identified as SRT agents in mucopolysacchar-
idoses (Piotrowska et al., 2006; Arfi et al., 2010; Kloska
et al., 2011).
Targeting Proteostasis
The combination of PCs with other molecules that
promote general protein folding has shown synergistic
effects in Gaucher’s- and Tay Sachs-derived patient fibro-
blasts (Mu et al., 2008b). The proteostasis regulator celas-
trol was used in combination with the PC NN-DNJ and
enhanced the restoration of mutant enzyme function.
Proteostasis modulators that affect calcium flux, such as
the L-type calcium channel blockers diltiazem and vera-
pamil, have been shown to enhance enzyme function in
fibroblasts from patients with Gaucher’s disease, a-
mannosidosis, and type IIIa MPS (Mu et al., 2008a; Ong
et al., 2010). Diltiazem inhibits and stabilizes glucocere-
brosidase at ER pH; therefore, as well as acting as a gen-
eral proteostasis modulator, this may be acting directly as
a PC in this setting (Rigat and Mahuran, 2009). This class
of therapeutic increases the ability of the cell to cope with
misfolding-prone proteins and may prove useful in target-
ing a range of different mutations or diseases, helping to
overcome many of the mutation-dependent chaperone
effects currently observed.
FUTURE CHALLENGES
Despite the recent progress in identifying and characterizing
small molecules that elicit chaperoning effects on GALC in
vitro, significant challenges still exist that must be overcome
to translate PCs into viable treatment options for those
who suffer from KD. The significant CNS involvement
poses one of the greatest challenges in the development of
KD therapeutics. PCT is one strategy that has the potential
to overcome this; however, the limitations in our current
understanding of both the mechanisms of chaperone–
enzyme interaction and the underlying causative mecha-
nisms associated with specific mutations in KD sufferers
highlight the requirement for additional investigation. Spe-
cific concerns relating to those chaperones investigated to
date for KD are listed below.
GALC Specificity
Although specificity for beta-configured
galactosidases has been shown for active-site-directed
chaperones, obtaining specificity for GALC vs. b-gal has
proved to be extremely difficult. Evaluating this specific-
ity relies on the use of both appropriate assays and sub-
strates when measuring the chaperone response. Also,
because of the structural similarity of the active sites of
these two enzymes, to confer this specificity it may be
essential to focus on modifications of the aglycone region
of PC candidates rather than the azasugar portion.
Off-Target Effects of Allosteric Chaperones
To overcome problems experienced with inhibition
of the target enzyme, nonactive site inhibitors are used;
however, these have the potential to elicit significant off-
target effects. Because these are directed away from the
active site, off-target effects are difficult to predict, moni-
tor, and overcome. During chaperone development, the
dosing strategy may become particularly important when
using this class of chaperone.
Mutation-Dependent Chaperone Effects
It is likely that only a subset of missense mutations
will respond to specific chaperones. There are two major
implications of this. First, candidate chaperones may be
missed if the number of mutations being screened is not
sufficiently large or if the selection of potentially respon-
sive mutations is not appropriately made. Second, devel-
opment and administration of multiple therapeutic
interventions may be required for successful treatment. As
an alternative strategy, proteostasis regulators, used care-
fully, may represent a broad-spectrum therapy that could
overcome mutation-dependent effects.
Measurement of Chaperone Efficacy
Currently, increased activity is the main readout of
chaperone efficacy, which may be misleading. A clear
readout of improved lysosomal delivery of functional
material is required to assess comprehensively the effec-
tiveness of PCT. Measuring the effectiveness of any of the
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chaperones discussed here requires the development of
alternative assays that are more amenable to high-
throughput approaches than are currently available.
CONCLUSIONS
The past decade has seen PCT emerge as a viable and
promising therapeutic option for LSDs. The dominating
presence of CNS pathology in KD has undoubtedly hin-
dered the acceleration of research and clinical translation
in this area with respect to other non-CNS LSDs. Despite
this, the use of PCT for KD does show promise, and sev-
eral GALC candidate chaperones have been identified.
Because of the difficulty of establishing a clear genotype–
phenotype correlation, it is clear that a detailed mechanis-
tic understanding of both the candidate chaperone and
the underlying target mutation will allow enhanced trans-
lation of successful therapy. However, it is evident that
the measurement of chaperone efficacy should be based
on several complementary biological assays that monitor
the ability of a chaperone not only to increase enzyme
activity but also to promote correct trafficking to the lyso-
somal compartments. Therefore, although increased
GALC activity is an important readout, we believe it
should not be the sole determinant of a successful chaper-
one. The parallel development of multiple therapeutic
approaches is likely to be the most successful way to target
the complex phenotypes observed in KD, and the identi-
fication of new PCT candidates is a critical contribution
to future therapeutic interventions for this debilitating
disorder.
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